Diagnosing multiple sclerosis is the easy part. Telling a newly diagnosed 30-year-old whether they will still be walking unaided in ten years is not. A retrospective study in Molecular Neurobiology tested whether lipidomics biomarkers taken once, from cerebrospinal fluid drawn at the diagnostic lumbar puncture, carry that missing prognostic signal. The group quantified a single lipid, 18:2 cholesterol ester, in CSF from 115 treatment-naive patients and 57 matched controls, th

NT-proBNP anchors nearly every heart failure risk score, and it still leaves teams guessing about who dies within two years. A clinical proteomics study of 1,212 adults with reduced ejection fraction asked whether broader plasma protein profiling closes that gap. Patane and colleagues measured 734 circulating proteins and derived a nine-protein panel that beat NT-proBNP alone. The instructive part is where the gain vanished: chronic Chagas cardiomyopathy, the group they most

Blood tests for early cancer detection keep failing at the same hurdle: a marker that looks strong against healthy donors fades once it meets patients with symptoms but no tumor. A Swedish group measured 165 plasma proteins and 244 NMR metabolite parameters in 2,066 people, hunting for multi-omics combinations of two to four analytes able to beat assays already in the clinic. Key Takeaways A four-protein plasma panel separated colorectal cancer patients from healthy controls

Only about a quarter of people whose sputum grows Mycobacterium avium complex (MAC) have progressive lung disease. The rest are colonized, and separating the two rests on nonspecific cough and CT patterns that blur into the bronchiectasis these patients already carry. A two-hospital Taiwanese study took that problem to blood transcriptomics, sequencing RNA from peripheral blood mononuclear cells (PBMCs) in 120 culture-positive patients. Key Takeaways Blood transcriptomics sep

Chronic lung allograft dysfunction ends most lung transplants after the first year, and spirometry only flags it once the airway remodelling is permanent. A prospective Melbourne cohort of 69 recipients tried to move that window earlier, running multi-omics profiling on surveillance bronchoalveolar lavage out to 30 months post-transplant. What separated the 13 patients who later developed CLAD was not infection. It was an endothelial glycocalyx and neutrophil-recruitment prog